Skip to main content
Erschienen in: Current Allergy and Asthma Reports 6/2024

19.04.2024 | Review

Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management

verfasst von: Aikaterini Anagnostou, Andrew Yaworsky, Monica Brova, Nazifa Ibrahim, Siddharth Kakked, Sasha Spite, Linette Duluc, Alan L. Shields, Tricia Lee, Stephanie Leonard, Kathy Przywara, Amelia Smith

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid’s content to better reflect patients’ and caregivers’ lived experience.

Recent Findings

Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4–17 years old.

Summary

An advisory board of allergy therapy experts (n = 3) and patient advocates (n = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chan ES, Dinakar C, Gonzales-Reyes E, et al. Unmet needs of children with peanut allergy: aligning the risks and the evidence. Ann Allergy Asthma Immunol. 2020;124(5):479–86.CrossRefPubMed Chan ES, Dinakar C, Gonzales-Reyes E, et al. Unmet needs of children with peanut allergy: aligning the risks and the evidence. Ann Allergy Asthma Immunol. 2020;124(5):479–86.CrossRefPubMed
3.
Zurück zum Zitat Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics. 1998;102(1):e6.CrossRefPubMed Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics. 1998;102(1):e6.CrossRefPubMed
4.
Zurück zum Zitat Hourihane JO, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. Clin Exp Allergy. 1997;27(6):634–9.CrossRefPubMed Hourihane JO, Kilburn SA, Dean P, Warner JO. Clinical characteristics of peanut allergy. Clin Exp Allergy. 1997;27(6):634–9.CrossRefPubMed
5.
Zurück zum Zitat Sicherer SH, Warren CM, Dant C, Gupta RS, Nadeau KC. Food allergy from infancy through adulthood. J Allergy Clin Immunol Pract. 2020;8(6):1854–64.CrossRefPubMedPubMedCentral Sicherer SH, Warren CM, Dant C, Gupta RS, Nadeau KC. Food allergy from infancy through adulthood. J Allergy Clin Immunol Pract. 2020;8(6):1854–64.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat • Tedner SG, Asarnoj A, Thulin H, Westman M, Konradsen JR, Nilsson C. Food allergy and hypersensitivity reactions in children and adults-a review. J Intern Med. 2022;291(3):283–302. This paper highlights the prevalence and etiology of peanut allergy, and describes current strategies in food allergy treatment and management, including oral immunotherapy (OIT). The authors articulate factors that patients and caregivers should consider when deciding whether or not to puruse OIT treatment including time, cost, and motivation.CrossRefPubMed • Tedner SG, Asarnoj A, Thulin H, Westman M, Konradsen JR, Nilsson C. Food allergy and hypersensitivity reactions in children and adults-a review. J Intern Med. 2022;291(3):283–302. This paper highlights the prevalence and etiology of peanut allergy, and describes current strategies in food allergy treatment and management, including oral immunotherapy (OIT). The authors articulate factors that patients and caregivers should consider when deciding whether or not to puruse OIT treatment including time, cost, and motivation.CrossRefPubMed
7.
Zurück zum Zitat Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141(1):41–58.CrossRefPubMed Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141(1):41–58.CrossRefPubMed
8.
Zurück zum Zitat DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: a multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020;75(11):2899–908.CrossRefPubMed DunnGalvin A, Blumchen K, Timmermans F, et al. APPEAL-1: a multiple-country European survey assessing the psychosocial impact of peanut allergy. Allergy. 2020;75(11):2899–908.CrossRefPubMed
9.
Zurück zum Zitat Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: a comprehensive literature review. Allergy. 2021;76(5):1367–84.CrossRefPubMed Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: a comprehensive literature review. Allergy. 2021;76(5):1367–84.CrossRefPubMed
10.
Zurück zum Zitat Venter C, Sicherer SH, Greenhawt M. Management of peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):345–355.e342.CrossRefPubMed Venter C, Sicherer SH, Greenhawt M. Management of peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):345–355.e342.CrossRefPubMed
11.
Zurück zum Zitat Poirot E, He F, Gould LH, Hadler JL. Deaths, hospitalizations, and emergency department visits from food-related anaphylaxis, New York City, 2000–2014: implications for fatality prevention. J Public Health Manag Pract. 2020;26(6):548–56.CrossRefPubMedPubMedCentral Poirot E, He F, Gould LH, Hadler JL. Deaths, hospitalizations, and emergency department visits from food-related anaphylaxis, New York City, 2000–2014: implications for fatality prevention. J Public Health Manag Pract. 2020;26(6):548–56.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.CrossRefPubMed Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001.CrossRefPubMed
13.
Zurück zum Zitat Hourihane JO, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728–39.CrossRef Hourihane JO, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728–39.CrossRef
14.
Zurück zum Zitat Ciaccio C, Goldsobel AB, Anagnostou A, et al. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol. 2022;129(6):758–768.e754.CrossRefPubMed Ciaccio C, Goldsobel AB, Anagnostou A, et al. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol. 2022;129(6):758–768.e754.CrossRefPubMed
15.
Zurück zum Zitat Vickery BP, Vereda A, Nilsson C, et al. Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study. J Allergy Clin Immunol Pract. 2021;9(5):1879–1889.e1813.CrossRefPubMed Vickery BP, Vereda A, Nilsson C, et al. Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study. J Allergy Clin Immunol Pract. 2021;9(5):1879–1889.e1813.CrossRefPubMed
16.
Zurück zum Zitat Fernandez-Rivas M, Vereda A, Vickery BP, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2022;77(3):991–1003.CrossRefPubMed Fernandez-Rivas M, Vereda A, Vickery BP, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2022;77(3):991–1003.CrossRefPubMed
17.
Zurück zum Zitat Leonard SA, Ogawa Y, Jedrzejewski PT, et al. Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp. Front Allergy. 2022;3:1004056.CrossRefPubMedPubMedCentral Leonard SA, Ogawa Y, Jedrzejewski PT, et al. Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp. Front Allergy. 2022;3:1004056.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Brown KR, Baker J, Vereda A, et al. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: pooled summary of phase 3 and extension trials. J Allergy Clin Immunol. 2022;149(6):2043–2052.e2049.CrossRefPubMed Brown KR, Baker J, Vereda A, et al. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: pooled summary of phase 3 and extension trials. J Allergy Clin Immunol. 2022;149(6):2043–2052.e2049.CrossRefPubMed
19.
Zurück zum Zitat •• Portnoy J, Shroba J, Tilles S, et al. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp. Ann Allergy Asthma Immunol. 2023;130(5):649–56. This real-world study (conducted in a sample of patients age 4-17 years of age treated with PALFORZIA), characterizes a sample of patients with peanut allergy taking PALFORZIA in US clinical practice. The authors concludes that PALFORZIA was prescribed in a diverse set of patients and that these patients had high treatment persistence. The authors also describe the importance of shared decision-making between clinicians, the patient, and the patient's family for PALFORZIA treatment decisions, and describe the need for a shared decision-making tool to facilitate this process.CrossRefPubMed •• Portnoy J, Shroba J, Tilles S, et al. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp. Ann Allergy Asthma Immunol. 2023;130(5):649–56. This real-world study (conducted in a sample of patients age 4-17 years of age treated with PALFORZIA), characterizes a sample of patients with peanut allergy taking PALFORZIA in US clinical practice. The authors concludes that PALFORZIA was prescribed in a diverse set of patients and that these patients had high treatment persistence. The authors also describe the importance of shared decision-making between clinicians, the patient, and the patient's family for PALFORZIA treatment decisions, and describe the need for a shared decision-making tool to facilitate this process.CrossRefPubMed
20.
Zurück zum Zitat Bird JA, Spergel JM, Jones SM, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e473.CrossRefPubMed Bird JA, Spergel JM, Jones SM, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e473.CrossRefPubMed
21.
Zurück zum Zitat Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy. 2022;77(8):2534–48.CrossRefPubMed Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy. 2022;77(8):2534–48.CrossRefPubMed
22.
Zurück zum Zitat •• Casale TB, Irani AM. Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents. Expert Rev Clin Immunol. 2023;19(3):253–65. This article provides an overview of the current landscape of peanut allergy management, including treatment with PALFORZIA.CrossRefPubMed •• Casale TB, Irani AM. Peanut (Arachis hypogaea) allergen powder-dnfp for the mitigation of allergic reactions to peanuts in children and adolescents. Expert Rev Clin Immunol. 2023;19(3):253–65. This article provides an overview of the current landscape of peanut allergy management, including treatment with PALFORZIA.CrossRefPubMed
23.
Zurück zum Zitat Blaiss MS, Meadows JA, Yu S, et al. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States. J Manag Care Spec Pharm. 2021;27(4):516–27.PubMed Blaiss MS, Meadows JA, Yu S, et al. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States. J Manag Care Spec Pharm. 2021;27(4):516–27.PubMed
24.
Zurück zum Zitat Anagnostou A, Lawrence C, Tilles SA, et al. Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy. BMC Res Notes. 2022;15(1):273.CrossRefPubMedPubMedCentral Anagnostou A, Lawrence C, Tilles SA, et al. Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy. BMC Res Notes. 2022;15(1):273.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Portnoy J, Ciaccio CE, Beausoleil J, et al. Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice. AACI. 2022;18(1):37. Portnoy J, Ciaccio CE, Beausoleil J, et al. Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice. AACI. 2022;18(1):37.
26.
Zurück zum Zitat Anagnostou A. A practical, stepwise approach to peanut oral immunotherapy in clinical practice: benefits and risks. J Asthma Allergy. 2021;14:277–85.CrossRefPubMedPubMedCentral Anagnostou A. A practical, stepwise approach to peanut oral immunotherapy in clinical practice: benefits and risks. J Asthma Allergy. 2021;14:277–85.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70.CrossRefPubMed Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70.CrossRefPubMed
31.
Zurück zum Zitat Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA. 2009;302(16):1805–6.CrossRefPubMed Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA. 2009;302(16):1805–6.CrossRefPubMed
32.
Zurück zum Zitat Greenhawt M, Shaker M, Winders T, et al. Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Ann Allergy Asthma Immunol. 2020;125(1):90–6.CrossRefPubMed Greenhawt M, Shaker M, Winders T, et al. Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Ann Allergy Asthma Immunol. 2020;125(1):90–6.CrossRefPubMed
34.
Zurück zum Zitat Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks, CA: Sage Publications; 2005.CrossRef Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks, CA: Sage Publications; 2005.CrossRef
35.
Zurück zum Zitat Ericsson KA, Simon HA. Protocol analysis: verbal reports as data. Cambridge, MA: MIT Press; 1993.CrossRef Ericsson KA, Simon HA. Protocol analysis: verbal reports as data. Cambridge, MA: MIT Press; 1993.CrossRef
36.
Zurück zum Zitat Friese S. ATLAS.ti 9 windows - user manual. Berlin: ATLAS.ti Scientific Software Development GmbH; 2021. Friese S. ATLAS.ti 9 windows - user manual. Berlin: ATLAS.ti Scientific Software Development GmbH; 2021.
37.
Zurück zum Zitat Miles MB, Huberman AM. Qualitative data analysis. London: Sage Publications; 1994. Miles MB, Huberman AM. Qualitative data analysis. London: Sage Publications; 1994.
38.
Zurück zum Zitat Lewins A, Silver C. Using software in qualitative research: a step-by-step guide. London: Sage Publications; 2007.CrossRef Lewins A, Silver C. Using software in qualitative research: a step-by-step guide. London: Sage Publications; 2007.CrossRef
39.
Zurück zum Zitat Anagnostou A, Hourihane JO, Greenhawt M. The role of shared decision making in pediatric food allergy management. J Allergy Clin Immunol Pract. 2020;8(1):46–51.CrossRefPubMed Anagnostou A, Hourihane JO, Greenhawt M. The role of shared decision making in pediatric food allergy management. J Allergy Clin Immunol Pract. 2020;8(1):46–51.CrossRefPubMed
Metadaten
Titel
Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management
verfasst von
Aikaterini Anagnostou
Andrew Yaworsky
Monica Brova
Nazifa Ibrahim
Siddharth Kakked
Sasha Spite
Linette Duluc
Alan L. Shields
Tricia Lee
Stephanie Leonard
Kathy Przywara
Amelia Smith
Publikationsdatum
19.04.2024
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 6/2024
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-024-01146-w

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.